Processa Pharmaceuticals, Inc. (PCSA) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing "Next Generation Chemotherapy" (NGC) drugs designed to improve the safety and efficacy of existing FDA-approved oncology treatments. The company is currently focused on advancing its lead candidate, NGC-Cap, into Phase 2 clinical trials for breast cancer. The filing reflects a 1-for-20 reverse stock split effected in January 2024.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3.01) million | $(5.74) million | $(6.63) million |
| Net Loss Per Share (Basic/Diluted) | $(1.01) | $(2.11) | $(5.34) |
| Operating Expenses | $(3.08) million | $(5.89) million | $(6.82) million |
| Cash and Cash Equivalents (End of Period) | $5.57 million (as of June 30, 2024) | ||
| Net Cash Used in Operating Activities | $(5.39) million (YTD 2024) | ||
| Net Cash Provided by Financing Activities | $6.26 million (YTD 2024) | ||
| Total Liabilities | $1.58 million (as of June 30, 2024) | ||
| Accumulated Deficit | $(81.11) million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Financing Activity: In January 2024, the company completed a public offering raising $6.3 million in net proceeds through the sale of common stock, pre-funded warrants, and warrants. This significantly bolstered liquidity compared to the prior year.
- Operating Expenses:
- YTD Comparison: Total operating expenses decreased by approximately $0.93 million compared to the same period in 2023. This was driven by a $0.96 million decrease in professional fees (excluding a non-recurring warrant expense in 2023) and a $0.25 million decrease in stock-based compensation.
- Q2 Comparison: General and Administrative (G&A) expenses increased by $0.33 million quarter-over-quarter, primarily due to higher legal fees and executive salaries, partially offset by lower stock-based compensation.
- Cash Flow: Net cash used in operating activities increased by $1.22 million YTD compared to 2023, largely due to prepayments for the upcoming Phase 2 trial of NGC-Cap.
- Capital Structure: A 1-for-20 reverse stock split was executed in January 2024, reducing outstanding shares from ~24.6 million to ~1.29 million.
Outlook, Risks, and Management Commentary
- Clinical Progress: The company received FDA clearance for its Investigational New Drug (IND) application for NGC-Cap in breast cancer on July 24, 2024. The Phase 2 trial is being initiated, with the first patient expected to be dosed in Q3 2024.
- Liquidity and Going Concern: Management states that current cash reserves of $5.6 million are sufficient to fund operations into late 2024. The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for one year beyond the filing date without additional funding.
- Future Funding: The company has established an "At-The-Market" (ATM) offering facility to sell up to $2.4 million of common stock. Management plans to raise additional capital through equity or debt offerings to fund future trials.
- Legal Proceedings: A dispute exists with licensor Elion Oncology, Inc. regarding the termination of a license agreement for NGC-Cap. Elion notified Processa of termination in May 2024; Processa disputes this and has filed a lawsuit seeking declaratory and injunctive relief.
- Management Changes: Russell Skibsted was appointed Chief Financial Officer on July 16, 2024.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $5.6 million cash balance to fund the initiation of the Phase 2 trial and operations through late 2024, given the "substantial doubt" disclosure.
- License Dispute: Monitor the status of the litigation with Elion Oncology regarding the NGC-Cap license, as a loss could jeopardize the company's primary asset.
- Capital Raising: Track the utilization of the ATM facility and any new equity offerings required to extend the runway beyond late 2024.
- Clinical Milestones: Confirm the dosing of the first patient in the NGC-Cap Phase 2 trial by the end of Q3 2024 to meet diligence obligations.
- Dilution: Note the significant increase in outstanding shares (from ~1.29 million to ~2.87 million) following the January 2024 offering and subsequent issuances.